INTRODUCTION {#sec1-1}
============

Systemic lupus erythematosus (SLE) is a chronic, multisystem, autoimmune disorder that affects women (90%) more than men.\[[@ref1]\] SLE can involve almost all of the systems including the central nervous system and it can cause several neurological symptoms such as seizure, stroke, chorea, myelopathy and several psychiatric syndromes.\[[@ref2]\] During SLE, up to 75% of adult patients suffer neuropsychiatric manifestations, which occur even when the disease is clinically and serologically quiescent.\[[@ref3][@ref4]\] In SLE patients, the most common psychiatric disorder is depression.\[[@ref5]\] However, the prevalence of depression varies across populations from 17% to 75%.\[[@ref6][@ref7][@ref8]\] Mood disorders, including depression, were found to be associated with a lower health-related quality of life.\[[@ref4][@ref9]\] It was also reported that depression could negatively affect treatment outcomes in the form of nonadherence to recommended treatments and clinic appointments.\[[@ref10]\] However, when treated promptly, mood disorders could be resolved in around 50% of patients with SLE.\[[@ref9]\] Therefore, recognition of depression and providing adequate treatment are important aspects of optimal management of SLE.

The aim of this multicenter cross-sectional study was to determine the prevalence of depression and identify the relationship between depression and disease characteristics in Saudi patients with SLE.

PATIENTS AND METHODS {#sec1-2}
====================

Sixty-eight Saudi patients with SLE who attended Rheumatology Clinics at four tertiary referral hospitals in Saudi Arabia (King Fahad Medical City, Riyadh; Al Noor Specialist Hospital, Makkah; Security Forces Hospital, Riyadh, and King Abdulaziz Medical City, Riyadh) between April and September 2014 were enrolled in the study. Inclusion criteria were Saudi nationality, aged ≥16 years fulfilling the American College of Rheumatology Revised Criteria for the Classification of SLE and willingness to give written informed consent \[[Table 1](#T1){ref-type="table"}\].\[[@ref11]\] Patients with unstable medical conditions, impaired consciousness, significant visual impairment or lack of necessary communication skills to ensure the reliability of test scores were excluded from the study.\[[@ref11]\] Data on demographic parameters, clinical features and treatments were collected and recorded. Laboratory evaluations included complete blood profile, urinalysis, anti-double stranded DNA antibodies, serum complements C3 and C4 and antiphospholipid (aPL) antibodies. Additionally, lupus anticoagulant, immunoglobulin (Ig) G, IgM, anticardiolipins and anti-β2-glycoprotein 1 were reviewed in all patients to evaluate any association with depression. Global disease activity was evaluated by SLE Disease Activity Index (SLEDAI). Accordingly, the patients were divided into five subsets (0: no activity; 1--5: mild activity; 6--10: moderate activity; 11--20: high activity and ≥20: high activity). A validated Arabic Beck Depression Inventory (BDI) score was used to estimate the prevalence of depression and its severity.\[[@ref12]\] Scores for each category of BDI were interpreted as follows: 0--9: normal; 10--18: mild depression; 19--29: moderate depression and ≥30: severe depression.\[[@ref12]\]

###### 

American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Criterion              Definition
  ---------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Malar rash             Fixed erythema, flat or raised, over the malar eminence, tending to spare the nasolabial folds

  Discoid rash           Erythematous raised patches with adherent keratotic scaling and follicular plugging; atrophic scarring may occur in older lesions

  Photosensitivity       Skin rash as a result of unusual reaction to sunlight, by patient history or physician observation

  Oral ulcers            Oral or nasopharyngeal ulceration, usually painless, observed by a physician

  Arthritis              Nonerosive arthritis involving two or more peripheral joints, characterized by tenderness, swelling or effusion

  Serositis              Pleuritis; convincing history of pleuritic pain or rub heard by physician or evidence of pleural effusion\
                         OR\
                         Pericarditis; documented by electrocardiogram or rub or evidence of pericardial effusion

  Renal disorder         Persistent proteinuria \>500 mg/day or \>3+ if quantitation not performed\
                         OR\
                         Cellular casts: May be red cell, hemoglobin, granular, tubular or mixed

  Neurologic disorder    Seizures: In the absence of offending drugs or known metabolic derangement; e.g., uremia, ketoacidosis or electrolyte imbalance\
                         OR\
                         Psychosis: In the absence of offending drugs or known metabolic derangement; e.g., uremia, ketoacidosis or electrolyte imbalance

  Hematologic disorder   Hemolytic anemia: With reticulocytosis\
                         OR\
                         Leukopenia: \<4000/mm^3^ total\
                         OR\
                         Lymphopenia: \<1500/mm^3^ on two or more occasions\
                         OR\
                         Thrombocytopenia: \<100,000/mm^3^ in the absence of offending drugs

  Immunologic disorder   Anti-DNA: Antibody to native DNA in abnormal titer\
                         OR\
                         Anti-SM: Presence of antibody to SM nuclear antigen\
                         OR\
                         Positive finding of aPL antibodies based on\
                          An abnormal serum level of IgG or IgM anticardiolipin antibodies,\
                          A positive test result for lupus anticoagulant using a standard method OR\
                          A false-positive serologic test for syphilis known to be positive for at least 6 months and confirmed by *Treponema pallidum* immobilization or fluorescent treponemal antibody absorption test

  ANA                    Abnormal titer of ANA by immunofluorescence or equivalent assay at any point in time, in the absence of drugs known to be associated with drug-induced lupus syndrome
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

aPL -- Antiphospholipid; ANA-- Antinuclear antibody; Ig -- Immunoglobulin

Ethical approval for this study (Protocol no.: HAPO-01-R-010) was provided by the Ethics Committee of King Abdulaziz City for Science and Technology (KACST), Riyadh, on May 4, 2015. Each patient gave written consent before study enrollment.

Data were analysed using SPSS software version 17.0 (SPSS Inc., IL, USA) by standard methods. Chi-square test or Fisher\'s exact test, whichever was appropriate, was used for comparison of categorical variables. Analysis of variance was utilized to compare the difference among continuous variables. A two-tailed *P* \< 0.05 was considered as statistically significant.

RESULTS {#sec1-3}
=======

All 68 patients completed the Arabic BDI. There were 64 women and 4 men with a median age of 30 years (age range: 16--59 years) and median disease duration of 5 years. Almost half of the patients (48.5%) were married, 38.2% had postsecondary education and 83.8% were not actively employed \[[Table 2](#T2){ref-type="table"}\]. Based on the Arabic BDI score, 67.6% of patients were found to have depression; of them, 33.8%, 20.6% and 13.2% had mild, moderate and severe depression, respectively. Only one patient (1.5%) had suicidal ideation, but no patient had any previous suicide attempt. Twenty-two patients (33.2%) had recent disease exacerbation within the previous year. Eighty-four percent of patients had active SLE (mild: 36.8%, moderate: 30.9%, high: 11.8% and very high: 4.4%). Fifty-six patients (82.4%) had received corticosteroid therapy with a median duration of 48 months and median dose of 5 mg/day. Forty-six (67.6%) patients had been subjected to immunosuppressive therapies. Almost 28% had positive aPL but only 16.2% had aPL syndrome (APS) \[[Table 3](#T3){ref-type="table"}\]. Of the 17 patients (25%) with comorbidities, 10 had hypertension as the major comorbid condition. Surprisingly, only four patients received antidepressants. There was a significant difference in corticosteroid therapy use between patients with and without depression (*P* = 0.046). However, there was no association between disease activities (*P* = 0.661) or disease duration (*P* = 1.00) and depression. Neither positive aPL (*P* = 0.284) nor APS (*P* = 0.738) was associated with depression \[[Table 4](#T4){ref-type="table"}\].

###### 

Demographic characteristics of patients with systemic lupus erythematosus (*n* = 68)

  Characteristic              *n* (%)
  --------------------------- -------------
  Median age (range), years   30 (16--59)
  Gender                      
   Male                       4 (5.9)
   Female                     64 (94.1)
  Marital status              
   Single                     33 (48.5)
   Married                    33 (48.5)
   Divorced                   2 (2.9)
  Education                   
   Elementary                 6 (8.8)
   Secondary                  33 (48.5)
   Bachelor                   26 (38.2)
   None                       3 (4.4)
  Income group                
   Low                        4 (5.9)
   Intermediate               41 (60.3)
   High                       23 (33.8)
  Present employment          
   No                         57 (83.8)
   Yes                        11 (16.2)

###### 

Clinical characteristics and treatment details of patients with systemic lupus erythematosus (*n* = 68)

  Characteristic                        *n* (%)
  ------------------------------------- -----------
  Suicidal ideation                     
   No                                   67 (98.5)
   Yes                                  1 (1.5)
  Suicide attempt                       
   No                                   68 (100)
   Yes                                  0
  Disease exacerbation                  
   No                                   46 (67.6)
   Yes                                  22 (32.4)
  Comorbid condition                    
   No                                   51 (75.0)
   Yes                                  17 (25.0)
  SLEDAI score                          
   No activity (0)                      11 (16.2)
   Mild activity (1--5)                 25 (36.8)
   Moderate activity (6--10)            21 (30.9)
   High activity (11--20)               8 (11.8)
   Very high (≥20)                      3 (4.4)
  Use of steroid at study enrollment    
   No                                   12 (17.6)
   Yes                                  56 (82.4)
  Immunosuppressive therapy             
   No                                   22 (32.4)
   Yes                                  46 (67.6)
  Immunosuppressive drugs               
   Azathioprine                         19 (27.9)
   Cyclosporine                         1 (1.5)
   Cyclosporine/Mycophenolate mofetil   4 (5.9)
   Hydroxychloroquine                   41 (60.3)
   Methotrexate                         1 (1.5)
   Mycophenolate mofetil                20 (29.4)
   Rituximab/Azathioprine               1 (1.5)
   No drugs                             21 (30.9)
  Antidepressant                        
   No                                   64 (94.1)
   Yes                                  4 (5.9)
  aPL status                            
   Negative                             49 (72.1)
   Positive                             19 (27.9)
  APS                                   
   No                                   57 (83.8)
   Yes                                  11 (16.2)
  BDI score                             
   No depression (0--9)                 22 (32.4)
   Mild (10--18)                        23 (33.8)
   Moderate (19--29)                    14 (20.6)
   Severe (30--63)                      9 (13.2)

APS -- Antiphospholipid syndrome; aPL -- Antiphospholipid; SLEDAI -- Systemic Lupus Erythematosus Disease Activity Index; BDI -- Beck depression inventory

###### 

Differences in demographic and clinical characteristics between patients with and without depression

  Variables                    Patients without depression   Patients with depression   *P*
  ---------------------------- ----------------------------- -------------------------- -------
  Sex                                                                                   
   Male                        2 (50)                        2 (50)                     0.590
   Female                      20 (31.3)                     44 (68.8)                  
  Marital status                                                                        
   Single                      12 (36.4)                     21 (63.6)                  0.728
   Married                     10 (30.3)                     23 (69.7)                  
   Divorced                    0                             2 (100)                    
  Education                                                                             
   Elementary                  2 (33.3)                      4 (66.7)                   0.855
   Secondary                   9 (27.3)                      24 (72.7)                  
   Bachelor                    10 (38.5)                     16 (61.5)                  
   No education                1 (33.1)                      2 (66.7)                   
  Income                                                                                
   Low                         1 (25)                        3 (75)                     0.403
   Intermediate                11 (26.8)                     30 (73.2)                  
   High                        10 (43.5)                     13 (56.5)                  
  Employee status                                                                       
   No                          19 (33.3)                     38 (66.7)                  1.000
   Yes                         3 (27.3)                      8 (72.7)                   
  Suicidal idea                                                                         
   No                          22 (32.8)                     45 (67.2)                  1.000
   Yes                         0                             1 (100)                    
  Disease exacerbation                                                                  
   No                          17 (37.0)                     29 (63.0)                  0.241
   Yes                         5 (22.7)                      17 (77.3)                  
  Disease duration (months)                                                             
   ≤6                          1 (33.3)                      2 (66.6)                   1.00
   ≥6                          21 (32.3)                     44 (67.7)                  
  SLEDAI score                                                                          
   No activity (0)             4 (36.4)                      7 (63.6)                   0.661
   Mild activity (1--5)        7 (28.0)                      18 (72)                    
   Moderate activity (6--10)   9 (42.9)                      12 (57.1)                  
   High activity (11--20)      2 (25.0)                      6 (75.0)                   
   Very high (≥20)             0                             3 (100)                    
  Steroid use                                                                           
   No                          7 (58.3)                      5 (41.7)                   0.046
   Yes                         15 (26.8)                     41 (73.2)                  
  Immunosuppressive therapy                                                             
   No                          9 (40.9)                      13 (59.1)                  0.297
   Yes                         13 (28.3)                     33 (71.7)                  
  Antidepressant                                                                        
   No                          19 (29.7)                     45 (70.3)                  0.096
   Yes                         3 (75.0)                      1 (25.0)                   
  Comorbidities                                                                         
   No                          15 (29.4)                     36 (70.6)                  0.369
   Yes                         7 (41.2)                      10 (58.8)                  
  aPL                                                                                   
   Negative                    14 (28.6)                     35 (71.4)                  0.284
   Positive                    8 (42.1)                      11 (57.9)                  
  APS                                                                                   
   No                          18 (3.6)                      39 (68.4)                  0.738
   Yes                         4 (36.4)                      7 (63.6)                   

All values are presented as *n* (%). APS -- Antiphospholipid syndrome; aPL -- Antiphospholipid; SLEDAI -- Systemic lupus erythematosus disease activity index

DISCUSSION {#sec1-4}
==========

Depression is one of the most commonly reported neuropsychiatric symptoms in patients with SLE. However, the prevalence of depression shows a considerable variability (16--60%) in distinct populations.\[[@ref8][@ref13][@ref14][@ref15]\] The present study indicated a high prevalence (67.6%) of depression in Saudi patients with SLE. We used the validated Arabic BDI to assess the presence of depression. Although Zakeri *et al*. reported a high prevalence (60%) of depression among Iranian patients with SLE,\[[@ref8]\] the prevalence rate was lower than that found in the present study. The higher prevalence of depression in the present study could be because of various factors such as differences in assessment methods, length of follow-up, sample sizes and cultural and social backgrounds. The authors hypothesize that cultural and social differences regarding the acceptance of chronic illness as well as the unique lifestyle practices by women in Saudi Arabia can substantially increase the pressure on patients, particularly females, and thus impact their mental health. For instance, there was no difference in employment status between patients with and without depression in our study, which could be explained by cultural background where most of the females were dependent. Many depressive symptoms such as lethargy and increased pain overlapped with SLE symptoms and resulted in delayed or undiagnosed depression.

This study assessed if factors such as patients\' characteristics, disease duration and activity, drug therapy and APS contribute to increased prevalence of depression in patients with SLE.\[[@ref8]\] The results showed that there was no association between disease duration, disease activity or immunosuppressive therapies and BDI scores. The findings of the present study are in accord with the findings of other studies using SLEDAI.\[[@ref16][@ref17][@ref18]\] Using corticosteroids was the only factor that was associated with high BDI scores. However, no association was found between corticosteroid dose and depression (*P* = 0.516), as most of the study population (93%) were on low dose (≤15 mg) at the time of enrollment. In previous studies, depression was reported to be associated with corticosteroid therapies.\[[@ref19][@ref20][@ref21]\] In contrast, in a study that demonstrated major depression in patients with SLE, there was no significant difference in the mean dose of prednisone between SLE patients with and without major depression.\[[@ref19]\] These discrepancies could be explained by variable doses and durations of corticosteroids in different studies. Nevertheless, the association between corticosteroids and depression reinforces the need to minimize the dose and duration of exposure as much as possible to avoid inducing depression. Interestingly, in a study conducted to evaluate the effectiveness of treating lupus nephritis with an oral steroid-free regimen, 90% of patients achieved complete or partial remission at a median time of 37 weeks.\[[@ref22]\] Such encouraging results have huge potential benefits for patients with SLE because they may help avoid the steroid-related side effects, particularly mood and cognitive changes. We did not find any association between the presence of aPL or APS and depression, which was consistent with findings of previous studies.\[[@ref21][@ref23]\]

Another important finding was the low proportion of patients (\~6%) receiving antidepressants. van Exel *et al*. also reported a similar finding that only 7% of patients with SLE had received antidepressants.\[[@ref16]\] This finding, in our opinion, reflects inadequate recognition and treatment of depression in SLE. Consequently, we strongly recommend that patients with SLE should be routinely and carefully evaluated for depressive symptoms. When depression is suspected, adequate psychiatric consultation and appropriate treatment are necessary.

There were some limitations in our study. First, we used a self-reported questionnaire that, in a cross-sectional study, could have resulted in over- or understating certain findings. Second, this study had a relatively small sample size, and thus further studies should be conducted with a larger sample size to confirm the findings of this study. Finally, as most participants of the study were female, the findings of this study have limited generalizability.

As this was a multicenter study carried out in different regions of Saudi Arabia, we were able to estimate the prevalence rate of depression among Saudi patients with SLE, assess factors that might be related to depression and detect the important association with corticosteroids. To the best of our knowledge, this is the first-of-its-kind study conducted in Saudi Arabia.

CONCLUSIONS {#sec1-5}
===========

The study demonstrates high prevalence of depression among Saudi patients with SLE and highlights the need for routine and careful evaluation for depressive symptoms among these patients. Adequate psychiatric consultation and appropriate treatment are necessary in patients with SLE.
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